Literature DB >> 16344331

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

James K Hennan1, Robert E Swillo, Gwen A Morgan, James C Keith, Robert G Schaub, Robert P Smith, Hal S Feldman, Ketil Haugan, Joel Kantrowitz, Phil J Wang, Aqel Abu-Qare, John Butera, Bjarne D Larsen, David L Crandall.   

Abstract

The antiarrhythmic and cardioprotective effect of increasing gap junction intercellular communication during ischemia/reperfusion injury has not been studied. The antiarrhythmic peptide rotigaptide (previously ZP123), which maintains gap junction intercellular communication, was tested in dogs subjected to a 60-min coronary artery occlusion and 4 h of reperfusion. Rotigaptide was administered i.v. 10 min before reperfusion as a bolus + i.v. infusion at doses of 1 ng/kg bolus + 10 ng/kg/h infusion (n = 6), 10 ng/kg bolus + 100 ng/kg/h infusion (n = 5), 100 ng/kg bolus + 1000 ng/kg/h infusion (n = 8), 1000 ng/kg bolus + 10 mug/kg/h infusion (n = 6), and vehicle control (n = 5). Premature ventricular complexes (PVCs) were quantified during reperfusion. A series of four or more consecutive PVCs was defined as ventricular tachycardia (VT). The total incidence of VT was reduced significantly with the two highest doses of rotigaptide (20.3 +/- 10.9 and 4.3 +/- 4.1 events; p < 0.05) compared with controls (48.7 +/- 6.0). Total PVCs were reduced significantly from 25.1 +/- 4.2% in control animals to 11.0 +/- 4.4 and 1.7 +/- 1.3% after the two highest doses of rotigaptide. Infarct size, expressed as a percentage of the left ventricle, was reduced significantly from 13.2 +/- 1.9 in controls to 7.1 +/- 1.0 (p < 0.05) at the highest dose of rotigaptide. Ultrastructural evaluation revealed no differences in myocardial injury in the infarct area, area at risk, border zone, or normal zone in vehicle and rotigaptide-treated animals. However, rotigaptide did increase the presence of gap junctions in the area at risk (p = 0.022, Fisher's exact test). Rotigaptide had no effect on heart rate, blood pressure, heart rate-corrected QT interval, or left ventricular end-diastolic pressure. In conclusion, these results demonstrate that rotigaptide is a potent antiarrhythmic compound with cardioprotective effects and desirable safety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344331     DOI: 10.1124/jpet.105.096933

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury.

Authors:  Michael P O'Quinn; Joseph A Palatinus; Brett S Harris; Kenneth W Hewett; Robert G Gourdie
Journal:  Circ Res       Date:  2011-01-27       Impact factor: 17.367

2.  A computer model of engineered cardiac monolayers.

Authors:  Jong M Kim; Nenad Bursac; Craig S Henriquez
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

Review 3.  Regenerative therapies in electrophysiology and pacing: introducing the next steps.

Authors:  Gerard J J Boink; Michael R Rosen
Journal:  J Interv Card Electrophysiol       Date:  2010-12-16       Impact factor: 1.900

4.  Effect of skeletal muscle Na(+) channel delivered via a cell platform on cardiac conduction and arrhythmia induction.

Authors:  Gerard J J Boink; Jia Lu; Helen E Driessen; Lian Duan; Eugene A Sosunov; Evgeny P Anyukhovsky; Iryna N Shlapakova; David H Lau; Tove S Rosen; Peter Danilo; Zhiheng Jia; Nazira Ozgen; Yevgeniy Bobkov; Yuanjian Guo; Peter R Brink; Yelena Kryukova; Richard B Robinson; Emilia Entcheva; Ira S Cohen; Michael R Rosen
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-06-21

Review 5.  Connexin-mediated cardiac impulse propagation: connexin 30.2 slows atrioventricular conduction in mouse heart.

Authors:  Maria M Kreuzberg; Klaus Willecke; Feliksas F Bukauskas
Journal:  Trends Cardiovasc Med       Date:  2006-11       Impact factor: 6.677

6.  Characterization of gap junction remodeling in epicardial border zone of healing canine infarcts and electrophysiological effects of partial reversal by rotigaptide.

Authors:  Ester Macia; Elena Dolmatova; Candido Cabo; Alexandra Z Sosinsky; Wen Dun; James Coromilas; Edward J Ciaccio; Penelope A Boyden; Andrew L Wit; Heather S Duffy
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-04-14

Review 7.  Gap junctions.

Authors:  Morten Schak Nielsen; Lene Nygaard Axelsen; Paul L Sorgen; Vandana Verma; Mario Delmar; Niels-Henrik Holstein-Rathlou
Journal:  Compr Physiol       Date:  2012-07       Impact factor: 9.090

Review 8.  Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.

Authors:  Stefan Dhein; Anja Hagen; Joanna Jozwiak; Anna Dietze; Jens Garbade; Markus Barten; Martin Kostelka; Friedrich-Wilhelm Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-27       Impact factor: 3.000

9.  Protein kinase Cepsilon mediates salutary effects on electrical coupling induced by ischemic preconditioning.

Authors:  Thomas J Hund; Deborah L Lerner; Kathryn A Yamada; Richard B Schuessler; Jeffrey E Saffitz
Journal:  Heart Rhythm       Date:  2007-06-08       Impact factor: 6.343

Review 10.  Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation.

Authors:  Jeffrey W Holmes; Zachary Laksman; Lior Gepstein
Journal:  Prog Biophys Mol Biol       Date:  2015-11-23       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.